IP Library Granted Patent US 11,065,360
Granted Patent B2
US 11,065,360 · App. 16/097,473 · Granted Jul 20, 2021

Medical hydrogel composition, and medical hydrogel, preparation method therefor and application thereof

Inventors: Limin Lin (Guangdong, CN); Yaya Yang (Guangdong, CN); Cheng Ma (Guangdong, CN); Kunxue Deng (Guangdong, CN); Yuyu Yuan (Guangdong, CN)
Assignee: Medprin Regenerative Medical Technologies Co., Ltd.
A61L24/043A61L24/0015A61L24/0031A61L27/18A61L27/26A61L27/52A61L27/58A61L31/041A61L31/06A61L31/145A61L31/148
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,065,360
App. No.
16/097,473
Granted
Jul 20, 2021
Kind
B2
Abstract

A medical hydrogel composition, a medical hydrogel, a preparation method therefore and an application thereof, and a medical hydrogel kit. The medical hydrogel composition comprises a first component and a second component; the first component comprises polylysine and polyethylene imine; the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, and 4-arm-polyethylene glycol-succinimidyl carbonate; the degree of polymerization of the polylysine is 20 or more. The medical hydrogel is formed by reacting the first component with the second component of the medical hydrogel composition. The medical hydrogel kit comprises the medical hydrogel composition and a buffer solution used for dissolving the components of the medical hydrogel composition. The medical hydrogel has a degree of swelling of −10%-50%, and can be applied in narrow parts where cranial, spinal, and peripheral nerves are densely distributed.

Claims (8)

1. A medical hydrogel kit, comprising:

a first component comprising polylysine and polyethylene imine (PEI), wherein the polylysine is ε-polylysine having an average molecular weight of 3000 to 5000 Da or poly-L-lysine having an average molecular weight of 7500 to 300000 Da, the polylysine has a degree of polymerization of 20 or more, and the polylysine and the PEI have a mass ratio of 0.1 to 1;

a second component selected from the group consisting of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, 4-arm-polyethylene glycol-succinimidyl carbonate, and combinations thereof, wherein the second component has an average molecular weight of 10,000 to 20,000 Da; and

a saline solution,

wherein the first component, the second component and the saline solution react to form a medical hydrogel having a degree of swelling of 5% to 47% when mixed together, and

wherein the formed medical hydrogel has a complete in vivo degradation time from 5 to 8 weeks.

2. The medical hydrogel kit according to claim 1 , wherein the first component and the second component are stored separately.

3. The medical hydrogel kit according to claim 1 , wherein the saline solution has a pH of 7.0 to 7.4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2018
From: LIN, LIMIN; YANG, YAYA; MA, CHENG; DENG, KUNXUE; YUAN, YUYU
To: MEDPRIN REGENERATIVE MEDICAL TECHNOLOGIES CO., LTD.
Reel/Frame 047341/0870 →
Priority Claims (1)
CN 201610286118.4 · Apr 29, 2016 · national
Continuity (1)
Related Publication 20190142994A1 · May 16, 2019
Cited By (1)
US 12,728,245